Su­per­nus' non­stim­u­lant AD­HD drug Qel­bree gains ap­proval for adult use

Up to 90% of the chil­dren that are di­ag­nosed with at­ten­tion deficit hy­per­ac­tiv­i­ty dis­or­der re­tain the di­ag­no­sis in­to adult­hood. Now, those adults will have an­oth­er non­stim­u­lant op­tion for treat­ment, as the FDA ap­proved an ex­pand­ed in­di­ca­tion for the use of Su­per­nus Phar­ma­ceu­ti­cals’ prod­uct in adults.

The drug, Qel­bree, is now ap­proved for every­one above the age of 6 di­ag­nosed with AD­HD. There are rough­ly 16 mil­lion peo­ple in the US with the dis­or­der.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.